Protein folding and misfolding

Nature

Volumn 426, Issue 6968, 2003, Pages 884-890

  Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; AMINO ACIDS; CELLS; DISEASES; QUALITY CONTROL; SYNTHESIS (CHEMICAL);

BIOLOGICAL ACTIVITIES;

PROTEINS;

PROTEIN;

AMINO ACID SEQUENCE; CELL KINETICS; CELLULAR DISTRIBUTION; DISEASE COURSE; ENERGY CONSUMPTION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN QUALITY; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

EVOLUTION, MOLECULAR; HUMANS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEINS; SENILE PLAQUES;

EID: 0347357617     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02261     Document Type: Review

References (71)

1. Vendruscolo, M., Zurdo, J., MacPhee, C. E. & Dobson, C. M. Protein folding and misfolding: a paradigm of self-assembly and regulation in complex biogical systems. Phil. Trans. R. Soc. Lond. 361, 1205-1222 (2003).
2. Radford, S. E. & Dobson, C. M. From computer simulations to human disease: emerging themes in protein folding. Cell 97, 291-298 (1999).
3. Dobson, C. M., Sali, A. & Karplus, M. Protein folding: a perspective from theory and experiment. Angew. Chem. Int. Ed. Eng. 37, 868-893 (1998).
4. Wolynes, P. G., Onuchic, J. N. & Thirumalai, D. Navigating the folding routes. Science 267, 1619-1620 (1995).
5. Dill, K. A. & Chan, H. S. From Levinthal to pathways to funnels. Nature Struct. Biol. 4, 10-19 (1997).
6. Dinner, A. R., Sali, A., Smith, L. J., Dobson, C. M. & Karplus, M. Understanding protein folding via free energy surfaces from theory and experiment. Trends Biochem. Sci. 25, 331-339 (2000).
7. Baldwin, R. L. Protein folding: matching speed and stability. Nature 369, 183-184 (1994).
8. Eaton, W. A., Munoz, V., Thompson, P. A., Henry, E. R. & Hofrichter, J. Kinetics and dynamics of loops, α-helices, β-hairpins, and fast-folding proteins. Acc. Chem. Res. 31, 745-753 (1998).
9. Snow, C. D., Nguyen, H., Pande, V. S. & Gruebele, M. Absolute comparison of simulated and experimental protein-folding dynamics. Nature 420, 102-106 (2002).
10. Yang, W. Y. & Gruebele, M. Folding at the speed limit. Nature 423, 193-197 (2003).
11. Mayor, U. et al. The complete folding pathway of a protein from nanoseconds to microseconds. Nature 421, 863-867 (2003).
12. Plaxco, K. W., Simons, K. T. & Baker, D. Contact order, transition state placement and the refolding rates of single domain proteins. J. Mol. Biol. 277, 985-994 (1998).
13. Schuler, B., Lipman, E. A. & Eaton, W. A. Probing the free-energy surface for protein folding with single-molecule fluorescence spectroscopy. Nature 419, 743-747 (2002).
14. Fersht, A. R. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding (W.H. Freeman, New York, 1999).
15. Fersht, A. R. Transition-state structure as a unifying basis in protein-folding mechanisms: contact order, chain topology, stability, and the extended nucleus mechanism. Proc. Natl Acad. Sci. USA 97, 1525-1529 (2000).
16. Shea, J. E. & Brooks, C. L. From folding surfaces to folding proteins: a review and assessment of simulation studies of protein folding and unfolding. Annu. Rev. Phys. Chem. 52, 499-535 (2001).
17. Fersht, A. R. & Daggett, V. Protein folding and unfolding at atomic resolution. Cell 108, 573-582 (2002).
18. Vendruscolo, M., Paci, E., Dobson, C. M. & Karplus, M. Three key residues form a critical contact network in a transition state for protein folding. Nature 409, 641-646 (2001).
19. Makarov, D. E. & Plaxco, K. W. The topomer search model: a simple, quantitative theory of two-state protein folding kinetics. Protein Sci. 12, 17-26 (2003).
20. Baker, D. A surprising simplicity to protein folding. Nature 405, 39-42 (2000).
21. Roder, H. & Colon, W. Kinetic role of early intermediates in protein folding. Curr. Opin. Struct. Biol. 7, 15-28 (1997).
22. Sanchez, I. E. & Kiefhaber, T. Evidence for sequential barriers and obligatory intermediates in apparent two-state protein folding. J. Mol. Biol. 325, 367-376 (2003).
23. Khan, F., Chuang, J. I., Gianni, S. & Fersht, A. R. The kinetic pathway of folding of barnase. J. Mol. Biol. 333, 169-186 (2003).
24. Vendruscolo, M., Paci, E., Karplus, M. & Dobson, C. M. Structures and relative free energies of partially folded states of proteins. Proc. Natl Acad. Sci. USA 100, 14817-14821 (2003).
25. Cheung, M. S., Garcia, A. E. & Onuchic, J. N. Protein folding mediated by solvation: water expulsion and formation of the hydrophobic core occur after the structural collapse. Proc. Natl Acad. Sci. USA 99, 685-690 (2002).
26. Hardesty, B. & Kramer, G. Folding of a nascent peptide on the ribosome. Prog. Nucleic Acid Res. Mol. Biol. 66, 41-66 (2001).
27. Bukau, B. & Horwich, A. L. The Hsp70 and Hsp60 chaperone machines. Cell 92, 351-366 (1998).
28. Hartl, F. U. & Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295, 1852-1858 (2002).
29. Ellis, R. J. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 11, 114-119 (2001).
30. Schiene, C. & Fischer, G. Enzymes that catalyse the restructuring of proteins. Curr. Opin. Struct. Biol. 10, 4O-45 (2000).
31. Hammon, C. & Helenius, A. Quality control in the secretory pathway. Curr. Opin. Cell. Biol. 7, 523-529 (1995).
32. Kaufman, R. J. et al. The unfolded protein response in nutrient sensing and differentiation. Nature Rev. Mol. Cell Biol. 3, 411-421 (2002).
33. Wilson, M. R. & Easterbrook Smith, S. B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25, 95-98 (2000).
34. Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774 (2000).
35. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).
36. Thomas, P. J., Qu, B. H. & Pedersen, P. L. Defective protein folding as a basis of human disease. Trends Biochem. Sci. 20, 456-459 (1995).
37. Dobson, C. M. The structural basis of protein folding and its links with human disease. Phil. Trans. R. Soc. Lond. B356, 133-145 (2001).
38. Horwich, A. Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J. Clin. Invest. 110, 1221-1232 (2002).
39. Bullock, A. N. & Fersht, A. R. Rescuing the functions of mutant p53. Nature Rev. Cancer 1, 68-76 (2001).
40. Tan, S. Y. & Pepys, M. B. Amyloidosis. Histopathology 25, 403-414 (1994).
41. Kelly, J. W. Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101-106 (1998).
42. Sunde, M. & Blake, C. C. F. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50, 123-159 (1997).
43. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
44. Fändrich, M. & Dobson, C. M. The behaviour of polyamino acids reveals an inverse side-chain effect in amyloid structure formation. EMBO J. 21, 5682-5690 (2002).
45. Jiménez, J. L. et al. Cryo-electron microscopy of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18, 815-821 (1999).
46. Petkova, A. T. et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl Acad. Sci. USA 99, 16742-16747 (2002).
47. Chiti, F., Stefani, M., Taddei, N., Ramponi, G. & Dobson, C. M. Rationalization of mutational effects on protein aggregation rates. Nature 424, 805-808 (2003).
48. Caughey, B. & Lansbury, P. T. Jr. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
49. Bitan, G. et al. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl Acad. Sci. USA 100, 330-335 (2003).
50. Nilsson, M. R., Driscoll, M. & Raleigh, D. P. Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation. Protein Sci. 11, 342-349 (2002).
51. Schlunegger, M. P., Bennett, M. J. & Eisenberg, D. Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. Adv. Protein Chem. 50, 50, 61-122 (1997).
52. Bucciantini, M. et al. Inherent cytotoxicity of aggregates implies a common origin for protein misfolding diseases. Nature 416, 507-511 (2002).
53. Lashuet, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
54. Dobson, C. M. Protein folding and disease: a view from the First Horizon Symposium. Nature Rev. Drug Discov. 2, 154-160 (2003).
55. True, H. L. & Lindquist, S. L. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407, 477-483 (2000).
56. Chapman, M. R. et al. Role of escherichia coli curli operons in directing amyloid fiber formation. Science 295, 851-855 (2002).
57. Kelly, J. W. & Balch, W. E. Amyloid as a natural product. J. Cell Biol. 161, 461-462 (2003).
58. Broome, B. M. & Hecht, M. H. Nature disfavours sequences of alternating polar and non-polar amino acids: implications for amyloidogenesis. J. Mol. Biol. 296, 961-968 (2000).
59. Chiti, F. et al. Kinetic partitioning of protein folding and aggregation. Nature Struct. Biol. 9, 137-143 (2002).
60. Macario, A. J. L. & Macario, E. C. Sick chaperones and ageing: a perspective. Ageing Res. Rev. 1, 295-311 (2002).
61. Ramirez-Alvarado, M., Merkel, J. S. & Regan, L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl Acad. Sci. USA 97, 8979-8984 (2000).
62. Dumoulin, M. et al. A camelid antibody fragment inhibits amyloid fibril formation by human lysozyme. Nature 424, 783-788 (2003).
63. Prusiner S. B. Prion diseases and the BSE crisis. Science 278, 245-251 (1997).
64. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
65. Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002).
66. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 300, 486-489 (2003).
67. Stefani, M. & Dobson, C. M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. 81, 678-699 (2003).
68. Sherman, M. Y. & Goldberg, A. L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32 (2001).
69. Muchowski, P. J. et al. Hsp70 and Hsp40 chaperones can can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA 97, 7841-7846 (2000).
70. Cserniely, P. Chaperone overload is a possible contributor to 'civilization diseases'. Trends Genet. 17, 701-704 (2001).
71. Dobson, C. M. Getting out of shape-protein misfolding diseases. Nature 418, 729-730 (2002).